Jumonji Inhibitors Overcome Radioresistance in Cancer through Changes in H3K4 Methylation at Double-Strand Breaks by Bayo Fina, Juan Miguel et al.
ArticleJumonji Inhibitors Overcome Radioresistance in
Cancer through Changes in H3K4 Methylation at
Double-Strand BreaksGraphical AbstractHighlightsd Inhibition of JARID demethylases sensitizes cancers to
radiation in vitro and in vivo
d Radiotherapy increases JARID enzyme activity, and blocking
it prevents DNA repair
d H3K4me3 accumulates at and near DSBs and impedes
recruitment of DNA repair factors
d Human tumors with high levels of JARID1B expression are
resistant to radiotherapyBayo et al., 2018, Cell Reports 25, 1040–1050
October 23, 2018 ª 2018 The Author(s).
https://doi.org/10.1016/j.celrep.2018.09.081Authors
Juan Bayo, Tram Anh Tran, Lei Wang,
Samuel Pen˜a-Llopis, Amit K. Das,
Elisabeth D. Martinez
Correspondence
elisabeth.martinez@utsouthwestern.edu
In Brief
Radioresistance is an obstacle to lung
cancer cures. Bayo et al. reveal that
JARID1B removes H3K4me3 marks at
sites of DNA damage. Genetic or
pharmacological inhibition of JARID1B
robustly radiosensitizes cancers in vitro
and in vivo through defects in DNA repair,
providing a therapeutic option for
radioresistant tumors.
Cell Reports
ArticleJumonji Inhibitors Overcome Radioresistance
in Cancer through Changes in H3K4
Methylation at Double-Strand Breaks
Juan Bayo,1,3 Tram Anh Tran,2,5 Lei Wang,2,5 Samuel Pen˜a-Llopis,4 Amit K. Das,2,5 and Elisabeth D. Martinez1,2,6,*
1Department of Pharmacology, UT Southwestern Medical Center, Dallas, TX, USA
2Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center, Dallas, TX, USA
3Instituto de Investigaciones en Medicina Traslacional, CONICET, Universidad Austral, Argentina
4Division of Translational Oncology, Essen University Hospital, German Cancer Consortium (DKTK), Partner Site Essen and German Cancer
Research Center (DKFZ), Heidelberg, Germany
5These authors contributed equally
6Lead Contact
*Correspondence: elisabeth.martinez@utsouthwestern.edu
https://doi.org/10.1016/j.celrep.2018.09.081SUMMARY
We have uncovered a role for Jumonji inhibitors in
overcoming radioresistance through KDM5B inhibi-
tion. Pharmacological blockade of Jumonji demethy-
lases with JIB-04 leads to specific accumulation of
H3K4me3 at sites marked by gH2AX and impaired
recruitment of DNA repair factors, preventing resolu-
tion of damage and resulting in robust sensitization
to radiation therapy. In DNA-repair-proficient cancer
cells, knockdown of the H3K4me3 demethylase
KDM5B, but not other Jumonji enzymes, mimics
pharmacological inhibition, and KDM5B overexpres-
sion rescues this phenotype and increases radiore-
sistance. The H3K4me3 demethylase inhibitor PBIT
also sensitizes cancer cells to radiation, while an
H3K27me3 demethylase inhibitor does not. In vivo
co-administration of radiation with JIB-04 signifi-
cantly prolongs the survival of mice with tumors
even long after cessation of treatment. In human pa-
tients, lung squamous cell carcinomas highly ex-
pressing KDM5B respond poorly to radiation. Thus,
we propose the use of Jumonji KDM inhibitors as
potent radiosensitizers.
INTRODUCTION
Toxicity from and resistance to radiation therapy constitutes a
major obstacle to curative treatments for non-small cell lung can-
cer (NSCLC) and other solid malignancies. Current regimens for
radiation therapy employ radiation alone or concurrent with cy-
cles of standard chemotherapy (Das et al., 2010; Song et al.,
2014). This is often limited by toxicity to normal tissues and is
complicated by the development of resistance (Anscher, 2010;
Crino` et al., 2010; Eberhardt et al., 2006; Falkson et al., 2017; Ho-
wington et al., 2013). Although the use of targeted therapies to
radiosensitize is not yet current practice, DNA repair inhibitors,
for example, have been tested in preclinical models and show ef-1040 Cell Reports 25, 1040–1050, October 23, 2018 ª 2018 The Auth
This is an open access article under the CC BY-NC-ND license (http://ficacy (Gil del Alcazar et al., 2014, 2016; Provencio and Sa´nchez,
2014; Tofilon and Camphausen, 2009).
Ionizing radiation (IR) results in a wide variety of chromosomal
DNA damage, with double-strand DNA breaks (DSBs) being the
main lesion involved inmitotic failure and cell death (Ward, 1988).
As a response to DSBs, a highly regulated signaling pathway is
activated to initiate repair mechanisms including homologous
recombination (HR) or non-homologous end joining (NHEJ), de-
pending on cell-cycle phase and cellular state (Chapman et al.,
2012; Jeggo et al., 2011). One of the earliest events in this
cascade is the phosphorylation by the serine/threonine kinase
ataxia telangiectasia mutated (ATM) of a histone variant, H2AX,
which marks sites of damage and triggers the recruitment of
the repair machinery (Firsanov et al., 2011; Karagiannis and El-
Osta, 2007; Kinner et al., 2008). 53BP1 is subsequently recruited,
and its Tudor domain is thought to function in reading themethyl-
ation state of the chromatin at damage sites (Mallette et al.,
2012). Other histone modifiers, especially methylation readers
and erasers, directly or indirectly also mediate aspects of DSB
repair (Fnu et al., 2011; Hunt et al., 2013; Watanabe et al.,
2013). In active euchromatic regions, for instance, it has been re-
ported that transcription is halted upon DNA damage, and this is
mediated at least in part by the recruitment of repressive com-
plexes, including PRC1, and by ubiquitination of H2A (Ui et al.,
2015; Wu et al., 2013). Heterochromatin regions marked by
H3K9me3 are more refractory to DSB repair (Goodarzi et al.,
2008; Janssen et al., 2016; Tsouroula et al., 2016), and thus,
for example, the Jumonji histone demethylases KDM4B and
KDM4D appear to be recruited to DSB sites early on to reduce
H3K9me3/H3K9me2 local levels (Young et al., 2013). A further
example is given by a recent report that uncovered a role of
JMJD5 or KDM8 in the late stages of HR via regulation of
H3K36me2 marks (Amendola et al., 2017).
We have identified and characterized an inhibitor of Jumonji
enzymes, JIB-04, that selectively targets lung cancer cells
versus normal cells (Bayo et al., 2015; Dalvi et al., 2017; Wang
et al., 2013). In the present study, we demonstrate that
JIB-04 and inhibitors of H3K4me3 demethylases, but not of
H3K27me3 demethylases, sensitize radioresistant NSCLC to
radiation, impairing both NHEJ and HR. JIB-04 causes theor(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. JIB-04 Robustly Sensitizes Radio-
resistant NSCLC to IR
(A and B) Clonogenic survival of H1299 (A) or A549
(B) cells treated with 16 nM or 25 nM JIB-04,
respectively, and then irradiated as indicated
(0–8 Gy). The survival of cells treated with JIB-04
alone was set to 1. Graphs show one of two in-
dependent experiments, each done in triplicate.
Error bars represent SD across triplicates. ***p <
0.001, DMSO or Z-isomer versus JIB-04 (A) (2-way
ANOVA); ***p < 0.001, DMSO or Z-isomer versus
JIB-04 (2 way ANOVA).
(C and D) Clonogenic survival of H1299 (C) and
A549 (D) cells treated with increasing doses of JIB-
04 (0–40 nM) and 2 Gy IR. The number of colonies
was normalized to the colonies formed by cells
treated with the corresponding dose of JIB-04
alone (without IR). Graph represents one of two
experiments (n = 3). Error bars show SD. *p < 0.05;
**p < 0.01 versus vehicle (0 nM) (Kruskal-Wallis).
See also Figure S1 and Table S1.retention of H3K4me3 marks near DSBs and impairs recruitment
of repair factors. Overexpression of the H3K4me3 demethylase
KDM5B, a target of JIB-04 inhibition, rescues the DNA repair de-
fects induced by JIB-04. Increasing the levels of KDM5B also
abolishes the radiosensitization action of JIB-04 and promotes
radiation resistance. In vivo, Jumonji inhibition robustly en-
hances the effects of radiation treatment and prolongs survival.
Analysis of cancer patient data uncovered a correlation between
high expression of KDM5B and radiation resistance in human
lung tumors. This work suggests that KDM5B plays an essential
role in the repair of DSB at transcriptionally active loci and has
implications for the treatment of radiation resistant cancers
and for achieving enhanced response to radiation therapy in pa-
tients. Thus, we provide proof-of-principle studies in support of
the use of Jumonji or KDM5 inhibitors to overcome radiation
resistance.
RESULTS
Inhibition of Jumonji Enzymeswith JIB-04 Enhances the
Response of Cancer Cells to Radiation
We first evaluated whether inhibition of Jumonji histone deme-
thylases, which should increase histone methylation, would alter
the response to radiation due to the underlying known connec-
tions between histone methylation and DNA repair. To this
end, we treated radioresistant NSCLC lines H1299 or A549
with our pan-selective Jumonji inhibitor JIB-04 (Dalvi et al.,
2017; Martinez and Gazdar, 2016; Wang et al., 2013) or vehicle,
and then exposed the cells to increasing levels of IR. Colony-for-
mation IC50 doses of JIB-04 were calculated to be in the nano-
molar range (Figure S1A) and were used in combination with
radiotherapy in standard colony-formation assays. Treatment
with JIB-04 4 hr prior to IR exposure robustly increased the
intrinsic radiosensitivity of these radioresistant cell lines (Figures
1A and 1B) and markedly decreased the surviving fraction at2 Gy radiation (SF2) (Table S1). Only the active E-isomer of
JIB-04 had this radiosensitizing effect, which was not observed
with the inactive Z-isomer (Wang et al., 2013). Sensitization to ra-
diation and decreased SF2 were also seen for multiple other
strongly or moderately radioresistant NSCLC lines tested, as
well as for other tumor types (Table S1; Figures S1B and S1C).
These changes in SF2 values are more robust than what has
been reported, such as for PARP1 inhibitors in various cancer
types (Lesueur et al., 2017). Interestingly, the dose enhancement
ratio at 25% cell kill, DER25 (the radiation dose required to
reduce the survival fraction to 25% in the absence or presence
of JIB-04) was higher for cells that were more radioresistant
and consequently had high SF2 values than for cells with intrin-
sically lower SF2 values (Table S1). Additionally, the radiosensi-
tization caused by JIB-04, as measured by decreasing SF2
values, was dose dependent (Figures 1C and 1D).
To evaluate the optimal timing of Jumonji inhibition for
enhancing the response to radiation, we compared the effects
of administering JIB-04 prior to versus after IR in NSCLC lines
(Figure S1D). Sensitization was observed under both conditions
but was significantly more robust when administering JIB-04
4 hr prior to IR (Figure S1E). Thus, the radiosensitization action
of JIB-04 is most effective before DNA repair begins in response
to radiation damage. Taken together, these data suggest the
Jumonji inhibitor may act upstream of or impact DNA repair.
gH2AX and 53BP1 Foci Resolution after IR Is Delayed by
JIB-04, but Not GSK-J4, Treatment
To determine whether JIB-04 radiosensitizes cells by affecting
DNA repair, repair-proficient NSCLC cells (H1299 and A549)
were pretreated for 4 hr with colony-formation IC50 doses of
this pan-Jumonji inhibitor (Figure S1A) and then exposed to IR
in the continuous presence of the drug. In JIB-04-treated cells,
ATM signaling was activated in response to IR similar to the
vehicle control (Figure S2A) and gH2AX foci formation was alsoCell Reports 25, 1040–1050, October 23, 2018 1041
Figure 2. Defective Resolution of gH2AX and 53BP1 Foci in JIB-04-Treated Cells
(A and B) DNA DSB repair kinetics after IR in H1299 (A) and A549 (B) cells. Cells were incubated with DMSO vehicle or JIB-04 for 4 hr (16 nM for H1299 and 25 nM
for A549), irradiated (2 Gy), fixed at the indicated time points, and then immunostained for gH2AX (red) and 53BP1 (green). Scale bars, 10 mm. Foci per nucleus
were counted (> 100 nuclei per treatment). Representative images are shown in the left panels for 15min and 12 hr. Repair kinetics are plotted as the percentage +
SEM of remaining foci against time in the right bar graphs for measured time points. ***p < 0.001; **p < 0.01 versus control (ANOVA). Representative data from one
of three independent experiments are shown. See also Figures S2 and S3 and Table S2.intact (Figures 2A and 2B, 15 min, red channel). However, the
time-dependent decrease in gH2AX foci corresponding to dam-
age resolution was significantly impaired in the presence of JIB-
04 (Figures 2A and 2B, red channel and upper bar graphs) with
>30%of foci remaining unresolved even at late time points. Simi-
larly, 53BP1 foci resolution was defective in cells treated with IR
plus JIB-04 compared to IR alone, and foci accumulation re-
mained (Figures 2A and 2B, green channel and lower bar graph).
The same was true in other radioresistant NSCLC lines (Table
S2). Importantly, JIB-04 on its own did not cause DNA damage
(Figure S2B). JIB-04 also prevented resolution of DNA damage
in prostate cancer LNCaP cells (Figure S2C). Furthermore, the
defects in DNA repair dynamics induced by JIB-04 were not
the result of altered distribution of cells through the cell cycle
or of preventing the signature G2/M arrest caused by IR (Figures
S3A and S3B).1042 Cell Reports 25, 1040–1050, October 23, 2018We then evaluated the effects of another Jumonji inhibitor,
GSK-J4, on the DNA repair process. In contrast to the pan-inhi-
bition of Jumonji enzymes seen with JIB-04 (Dalvi et al., 2017;
Wang et al., 2013), GSK-J4 has been reported to more specif-
ically target Jumonji H3K27 demethylases at low or moderate
doses (Kruidenier et al., 2012). We have previously confirmed
that in NSCLC cells, including H1299, GSK-J4 only affects
H3K27me3 demethylation and not H3K4me3 or H3K9me3 de-
methylation and that this specificity is maintained in vivo (Dalvi
et al., 2017; see Figure 6F in Dalvi et al., 2017). Here, we first es-
tablishedGSK-J4’s potency against H1299 andA549NSCLCs in
colony-formation assays (Figure S3C) and then exposed cells to
IC50 doses in the presence of radiation, as done with JIB-04. In
contrast to JIB-04, however, GSK-J4 failed to sensitize radiore-
sistant NSCLC cells (Figure S3D). Consistent with this result,
GSK-J4 had no impact on the resolution of IR-induced damage
Figure 3. The Radiosensitizing Effects and DNA Repair Defects Induced by JIB-04 Are Cancer Selective
(A) JIB-04 IC50 determined by liquid colony formation in immortalized non-transformed human bronchial epithelial cells HBEC3KT and HBEC30KT. Graph
represents one experiment done in triplicate.
(B) Clonogenic survival of HBEC3KT and HBEC30KT cells treated with 600 nM or 500 nM JIB-04, respectively, and then irradiated as indicated. Curves were
derived as in Figure 1B. Graph represents one of three experiments done in triplicate. Values represent the average survival fraction ± SD of triplicate samples. ns
indicates that no significant differences in radiosensitization curves across treatments were observed (pR 0.1, 2-way ANOVA).
(C) DNA DSB repair kinetics in HBEC30KT cells. Cells were incubated with vehicle or 500 nM JIB-04 for 4 hr, irradiated (2 Gy), fixed, immunostained for gH2AX,
and then quantified as in Figure 2. Representative images are shown on the left panel. Scale bars, 10 mm. Repair kinetics are plotted in the right bar graphs as
percentage + SEM of remaining foci over time. ns indicates that no significant differences were observed between vehicle and treatment groups at any time point
(p > 0.8, ANOVA). Data are from >50 nuclei per treatment for one of two experiments.
See also Figure S3.as measured by gH2AX or 53BP1 foci resolution in H1299 (Fig-
ure S4A) or A549 cells (Figure S4B). This indicated that targets
specific to JIB-04, but not GSK-J4, under the tested conditions
(likely H3K4me3 and/or H3K9me3 demethylases) (see Dalvi
et al., 2017, Figures 6F and 6G) play a role in DNA repair dy-
namics and radiation sensitivity in NSCLC.
Inhibition of Jumonji Enzymes Does Not Radiosensitize
or Affect the DNA Repair Dynamics of Normal Cells
We have previously established that JIB-04 specifically inhibits
the viability of cancer cells, but not normal cells, and selectively
alters cancer cell transcription (Dalvi et al., 2017; Wang et al.,
2013). To determine whether the effect of JIB-04 on DNA repair
dynamics described above was also cancer-selective, we
evaluated the response to radiation of two different normal hu-
man bronchial epithelial cell (HBEC) lines derived from two
distinct patients and immortalized for culture, HBEC3KT and
HBEC30KT, which remain non-tumorigenic (Sato et al., 2006,
2013). IC50 doses of JIB-04 in colony-formation assays (Fig-
ure 3A) were used to pretreat cells 4 hr prior to radiation, and
then survival was measured as before. Remarkably, JIB-04 did
not radiosensitize these normal cells (Figure 3B). In agreement
with these findings, in normal cells treated with inhibitor, no de-
fects were found in gH2AX foci formation in response to IR in foci
resolution over a time course (Figure 3C), or in DNA damagesignaling (Figure S3E). These data indicate that the DNA repair
deficiency and consequent radiosensitization triggered by
JIB-04 are cancer specific.
JIB-04 Lowers the Efficiency of Both NHEJ and HR
To understand the mechanism for the delayed resolution of IR-
induced damage seen in cancer cells in the presence of JIB-
04, we measured the efficiency of repair by NHEJ and HR,
the two main pathways of cellular DSB repair. Established
plasmid-based reporter systems were used for this purpose (Se-
luanov et al., 2010). H1299 cells containing the stably integrated
NHEJ or HR constructs depicted in Figure 4A were transfected
with an I-Sce1 expression vector to induce DNA breaks and
with an mCherry plasmid to control for transfection efficiency.
Transfected cells treated with JIB-04 or vehicle were then as-
sayed by fluorescence-activated cell sorting (FACS) for GFP
expression as a measure of repair. As demonstrated in Figures
4B and S5A, both NHEJ and HR were significantly inhibited in
the presence of JIB-04 to 50% or less of normal levels. These re-
sults were confirmed in other tumor types, which gave highly
similar results (Figures S5B–S5D). In addition, NSCLC cells
endogenously deficient in DNA repair and thus highly sensitive
to IR were not further sensitized by JIB-04 (Figure S5E). Taken
together, these findings point to a common upstream defect in
the repair of DSBs caused by JIB-04, affecting both NHEJ andCell Reports 25, 1040–1050, October 23, 2018 1043
Figure 4. JIB-04 Inhibits Both NHEJ and HR
Repair
(A) Schematic of the reporter constructs used in
HR and NHEJ repair assays.
(B) H1299 cells stably containing the NHEJ or the
HR constructs were treated with JIB-04 or DMSO
for 4 hr and then transfected with the pCMV3xnls-
I-SceI (functional endonuclease) and a pN1-
mCherry plasmid as transfection control in the
continuous presence of treatment (300 nM JIB-
04). Cells were analyzed by flow cytometry for GFP
and mCherry expression 24 hr after transfection.
20,000 cells were analyzed in each sample and
NHEJ or HR repair frequency calculated (%GFP+
cells/%mCherry+ cells). Average + SEM values of
triplicates for one of three representative experi-
ments are shown. ***p < 0.001 versus vehicle
control (Kruskal-Wallis).
(C–F) DNA-PKcs p-T2609 (C and D) and RAD51
(E and F) foci kinetics in H1299 cells. Cells were
incubated with vehicle or 16 nM JIB-04 for 4 hr,
irradiated (10 Gy), fixed, and immunostained, and
then the number of foci per nucleus in >100 cells
was counted for each time point. (C) and (E)
show representative immunofluorescence images
(scale bars, 10 mm), and (D) and (F) show foci for-
mation and resolution kinetics obtained by plotting
the percentage + SEM of cells with more than 5
foci per nucleus over time (***p < 0.001; **p < 0.01;
*p < 0.05 versus DMSO control per time point
[ANOVA]). Data are representative of one of two
independent experiments.
See also Figure S5.HR and leading to radiosensitization in DNA-repair-proficient
cells. Thus, we next measured the recruitment of repair factors
to sites of damage.
JIB-04 Blocks the Recruitment of DNA-PKcs and RAD51
to Sites of Damage and Inhibits Foci Resolution
The DNA-dependent protein kinase DNA-PKcs acts at sites
of damage to mediate repair by NHEJ. Since we observed
decreased efficiency of DNA repair by NHEJ after IR in cells
treated with JIB-04, we measured the dynamics of active DNA-
PKcs foci formation and resolution. H1299 cells treated with IR
readily formed DNA-PKcs pT2609 foci by 1 hr, and these foci
were largely resolved by 24 hr (Figures 4C and 4D, white bars).
In contrast, cells treated with JIB-04 plus IR exhibited a clear
deficiency in forming active DNA-PKcs foci with delayed foci for-
mation post-IR. In addition, the majority of DNA-PKcs pT2609
foci remained unresolved even 24 hr post-irradiation in the pres-
ence of the inhibitor (Figures 4C and 4D, black bars). Thus, JIB-
04 both impaired the timely recruitment of active DNA-PKcs to
sites of damage and blocked their resolution.
To determine whether JIB-04 was also impairing proper
recruitment of HR factors to sites of damage, we measured
RAD51 foci formation and resolution over a time course. Accu-
mulation of RAD51 near DSBs was not seen at 3 hr but was
readily detected by 6 hr in H1299 cells, consistent with the slower
timing of HR compared to NHEJ (Figures 4E and 4F, white bars).
JIB-04 treatment significantly diminished RAD51 recruitment
and additionally impaired foci resolution, with a large percentage1044 Cell Reports 25, 1040–1050, October 23, 2018of foci remaining at late time points (Figures 4E and 4F, black
bars). A similar behavior was observed in A549 cells (Figure S5F).
Collectively, these data confirm that JIB-04 affects an aspect of
DSB repair common to both NHEJ and HR.
Jumonji Inhibition by JIB-04 Results in H3K4me3, but
Not H3K9me3, Enrichment at DSBs
Heterochromatin marked by H3K9me3 ismore refractory to DNA
repair than euchromatin (Chiolo et al., 2013). In euchromatin,
H3K4me3 at transcriptionally active genes must likely be deme-
thylated uponDNAdamage in order to stop transcription until the
DNA is repaired (Aymard et al., 2014; Iacovoni et al., 2010; Seiler
et al., 2011; Solovjeva et al., 2007; Ui et al., 2015). Since inhibition
of Jumonji histone demethylase enzymes with JIB-04 can result
in increased histone methylation levels, we hypothesized that
H3K4me3 or H3K9me3 marks may be accumulating around
DSBs in drug-treated cells, contributing to defective repair factor
recruitment and defective resolution of damage. To test this pos-
sibility, we immunoprecipitated global DNA fragments digested
to single nucleosome size associated with gH2AX and then
measured H3K4me3 or H3K9me3 levels at these sites of
damage in cells treated with IR alone or with IR plus JIB-04
or DMSO vehicle. Surprisingly, there were no changes in
H3K9me3 levels induced by JIB-04 at nucleosomes marked by
gH2AX (Figures 5A and 5B, right panels). However, JIB-04 mark-
edly increased H3K4me3 at these sites (Figures 5A and 5B, left
panels). Consistent with this result, we found that the total enzy-
matic activity of H3K4me3 Jumonji demethylasess (Figure 5C),
Figure 5. Jumonji Inhibition by JIB-04 Re-
sults in H3K4me3 Enrichment at DSBs
(A) Cells were incubated with vehicle or 300 nM
JIB-04 for 4 hr, irradiated (20 Gy), and lysed,
and nucleosomes were solubilized. gH2AX was
immunoprecipitated from 2 mg soluble nucleo-
some extract and immunoprecipitates blotted for
gH2AX and H3K4me3 (left) or H3K9me3 (right).
(B) The immunoblot data from three independent
experiments were quantified and expressed as the
average ratio H3K4me3 signal/gH2AX signal or
H3K9me3 signal/gH2AX signal + SEM. *p < 0.05;
ns, not significant (p = 0.74); DMSO versus JIB-04
(t test).
(C and D) H1299 cells were pretreated with JIB-
04 (16 nM) for 4 hr followed by IR (8 Gy) and
collected at 15 min after radiation. Cellular ex-
tracts were prepared and H3K4me3 (C) and
H3K9me3 (D) activity measured. Values in (C) and
(D) are expressed as percentage + SEM of
DMSO-treated activity across three independent
experiments. *p < 0.05 IR versus JIB-04; **p <
0.001 IR versus DMSO; ***p < 0.001 IR versus
JIB-04+IR; ns, not significant (p > 0.8) (Kruskal-
Wallis).
(E) H1299-NHEJ stable cells pretreated with DMSO or 300 nM JIB-04 were transfected with I-Sce1 plasmid to induce DSBs, and 20 hr later, ChIP/re-ChIP
experiments were carried out by immunoprecipitating the product of gH2AX ChIP with H3K4me3 antibodies. Levels of associated DNA were measured by
qPCR. *p = 0.012 (DMSO versus JIB-04 for primer 1); *p = 0.011 (DMSO versus JIB-04 for primer 2); ns, p = 0.3 (DMSO versus JIB-04 for control region) (one-
tailed paired t test). n = 2–4 replicates of one experiment; average percentage of re-ChIP input relative to DMSO ± SEM is shown.
See also Figure S6.but not that of H3K9me3 demethylases (Figure 5D), could be
increased upon IR exposure and that just 4 hr of pretreatment
with JIB-04 blocked this IR-induced increase in enzyme activity
(Figures 5C and 5D). Under these experimental conditions, we
again observed accumulation of gH2AX but no measurable
changes in global histone marks (Figures S6A–S6C). While JIB-
04 treatment resulted in H3K4me3 accumulation at gH2AX-pos-
itive nucleosomes (Figures 5A and 5B, left panels), we did not
see significant defects in Ku70 recruitment or protein levels
after inhibition in NSCLC (Figures S6D and S6E), in contrast to
the defects seen in DNA-PKcs and RAD51 above. To confirm
that H3K4me3 levels were accumulating at DSBs, we performed
chromatin immunoprecipitation (ChIP)/re-precipitation (re-ChIP)
experiments in H1299 cells harboring an engineered I-Sce1 cut
site. Chromatin immunoprecipitation of DNA associated with
gH2AX followed by re-ChIP with H3K4me3 antibodies revealed
enrichment of DNA fragments at and adjacent to the site of
DSB in JIB-04 treated cells, as revealed by qPCR (Figure 5E).
This enrichment was not seen in a control genomic region (Fig-
ure 5E). Together, these results indicate that an H3K4me3
Jumonji demethylase enzyme(s) may be inhibited by JIB-04 dur-
ing the response to IR, leading to the specific accumulation of its
trimethylated histone substrate at transcriptionally active regions
harboring DNA damage.
Jumonji KDM Enzyme Knockdown Phenocopies the
JIB-04 Repair Defect, and Overexpression of KDM5B
Rescues It
To directly address whether JIB-04 was targeting a specific
Jumonji demethylase after IR, we evaluated whether genetic
downregulation of Jumonji demethylases would phenocopythe effects of JIB-04, resulting in defects in DSB repair. Knock-
down of KDM5B or KDM4B, but not of other H3K4me3 or
H3K9me3 Jumonji demethylases screened, resulted in accumu-
lation of unresolved gH2AX and 53BP foci (Figures S7A–S7D,
6A, and 6B). To define which of these enzymes might be the
target of JIB-04 in NSCLC leading to the drug-induced defect
in DSB repair, we performed rescue experiments. KDM5B, but
not KDM4B, overexpression rescued the JIB-04-induced accu-
mulation of unresolved gH2AX and 53BP foci (Figures 6C, 6D,
S7E, and S7F). The accumulation of unresolved DSBs seen in
KDM4B knockdown NSCLC cells (Figures 6A and 6B) is likely
due to further DNA damage, as has been reported to occur in
other cancer cell types upon KDM4B depletion (Chen et al.,
2014; Young et al., 2013; Zheng et al., 2014). Thus, among
H3K4me3 andH3K9me3 demethylases, KDM5Bplays an impor-
tant role in the DNA damage response, and its genetic or phar-
macological inhibition triggers a defect in DSB repair that can
be exploited therapeutically to enhance radiation sensitivity.
This is in line with the higher sensitivity to JIB-04 of KDM5/JARID
enzymes compared to other Jumonji demethylases that we have
observed in vitro (Wang et al., 2013). In further support of this
conclusion, the KDM5 inhibitor PBIT (Sayegh et al., 2013) also ra-
diosensitized multiple NSCLCs (Figures S7G and S7H) similar to
JIB-04 and in contrast to the lack of effect of GSK-J4 (Figure S4).
We used PBIT for this study because of its higher potency in our
system compared to the other available KDM5 inhibitor, CPI-455
(Vinogradova et al., 2016), as seen in Figures S7G and S7H.
These results are in agreement with the reported recruitment of
KDM5B to sites of DSBs seen in another system (Li et al.,
2014) and indicate a role for demethylation of H3K4me3 at tran-
scriptionally active loci harboring DNA damage in NSCLCs.Cell Reports 25, 1040–1050, October 23, 2018 1045
Figure 6. Jumonji Enzyme Knockdown Phenocopies the JIB-04 Repair Defect, and Overexpression of KDM5B Rescues the JIB-04-Induced
DNA Repair Defects and Radiosensitization of Cancer Cells
(A and B) DNA DSB repair kinetics in H1299 cells after knockdown of KDM5B or KDM4B. Cells were irradiated 48 hr after transfection (2 Gy) and immunostained
for gH2AX (A) and 53BP1 (B), and then the number of foci per nucleus were counted after 6 hr (>100 nuclei). Graphs represent the percent of foci remaining + SEM
for one of three equivalent independent experiments. ***p < 0.001; **p < 0.01; *p < 0.05 versus controls (ANOVA).
(C and D) DNA DSB repair kinetics showing gH2AX (C) or 53BP1 (D) in H1299 cells overexpressing FLAG-KDM5B or HA-KDM4B. 24 hr after transfection, cells
were incubated with 16 nM JIB-04 for 4 hr, irradiated (2 Gy), and processed as above. Graphs represent the percent of remaining foci + SEM6 hr after radiation for
one of three independent experiments. ***p < 0.001 versus controls; ns, p > 0.4 (ANOVA).
(E and F) Clonogenic survival of H1299 cells transfected with pcDNA3 empty vector or overexpressing KDM5B and treated with JIB-04 (E) or KDM5B-over-
expressing cells treated with DMSO versus JIB-04 (F). **p < 0.01 KDM5B+JIB-04 versus pcDNA3+JIB-04; ns, no significant difference (p = 0.5) KDM5B+JIB-04
versus KDM5B+DMSO (2-way ANOVA). Inset in (E) shows representative images of colony assays of cells transfected with pcDNA3 or overexpressing KDM5B
treated with JIB-04 and 8 Gy radiation. Inset in (F) is a western blot showing the overexpression of KDM5B in cells used for these studies. Data represent the
average of three to four independent experiments. Error bars represent SD across experiments.
See also Figure S7.To gain further mechanistic insights into the role of KDM5B in
DSB repair and the enhanced response to IR in the presence of
JIB-04, we overexpressed KDM5B in NSCLCs competent for
DNA repair and measured their survival to IR with or without
JIB-04. Remarkably, in line with the rescue of JIB-04-induced
gH2AX and 53BP1 foci accumulation (Figures 6C and 6D),
KDM5B overexpression also rescued the survival of JIB-04-
treated cells exposed to IR compared to control cells (Figure 6E).
Furthermore, KDM5B overexpression blocked JIB-04-mediated
radiosensitization and decrease in demethylase activity, while
control cells retained sensitivity and demethylase inhibition, con-
firming KDM5B is the main cellular target of JIB-04 yielding the
radiosensitization phenotype (Figures 6F and S7I–S7J).
JIB-04 Blocks H3K4me3 Demethylation In Vivo,
Radiosensitizes Tumors, and Prolongs the Survival of
Tumor-Bearing Mice
To determinewhether Jumonji inhibition results in radiosensitiza-
tion and tumor regression in vivo, we generated subcutaneous
tumors of H1299 cells. Tumors were established to a volume of
200 mm3 before initiating treatment with JIB-04, IR, or JIB-04
plus IR as described in detail in STAR Methods. JIB-04 was
used as the inhibitor of choice because of its known activity in1046 Cell Reports 25, 1040–1050, October 23, 2018mice (Dalvi et al., 2017; Wang et al., 2013) compared to other
KDM5 inhibitors. Treatment of tumor-bearingmicewith the com-
bination of JIB-04 plus IR gave robust synergistic inhibition of tu-
mor growth compared to either treatment alone (Figure 7A, left
panel). Indeed, tumors treated with the combined therapy grew
significantly slower than those treated with vehicle or either sin-
gle agent. This was seen, for example, by a large dose enhance-
ment factor of 6.5 for time to reach a volume of 500 mm3.
Whereas it took 5–8 days on average for tumors treated with
vehicle, JIB-04 alone, or IR to reach this volume, tumors in ani-
mals receiving JIB-04 with IR took 22 days to reach this size.
We also evaluated whether the radiosensitizing effects of JIB-
04 translated into longer survival of tumor-bearing animals after
treatment. As can be seen in Figure 7A (right panel), mice treated
with JIB-04 and IR survived significantly longer thanmice treated
with either agent alone or vehicle. This was a sustained effect,
maintained even weeks after the end of treatment, giving the an-
imals a median survival of 55 days compared to 14 days in the
vehicle-treated cohort, 16 days with JIB-04 alone, or 36 days
in the IR group. Thus, there was strong synergy between JIB-
04 and IR in vivo as shown by both robust reduction in tumor
growth rate and increased median survival, even after cessation
of treatment. Strong synergy between JIB-04 and IR in vivo and
Figure 7. JIB-04 Robustly Radiosensitizes
Tumors In Vivo and Prolongs the Survival
of Tumor-Bearing Mice
(A) Subcutaneous tumors generated from H1299
cells were allowed to reach a volume between 150
to 200 mm3 , and then mice were treated every
other day with vehicle (n = 9), JIB-04 50 mg/kg
(n = 8), IR (n = 9), or JIB-04 with IR (2 Gy, given 4 hr
after drug administration; n = 8) for a total of 12
doses. Graph represents the tumor volume (left)
and percent survival (right). DEF500 = (days to
reach 500 mm3 for JIB-04+IR-treated mice  days
to reach 500 mm3 for JIB-04 treated mice)/(days to
reach 500mm3 for IR-treatedmice days to reach
500 mm3 for vehicle-treated mice). Error bars
represent SEM.
(B) Subcutaneous tumors generated from A549
cells treated as described in (A) with vehicle (n = 8),
JIB-04 50mg/kg (n = 8), IR (n = 9), or JIB-04 with IR
(n = 10). Graph represents the tumor volume (left)
and percent survival (right). DEF400 was calcu-
lated as above for time to 500 mm3.
For (A) and (B), error bars represent SEM. ***p <
0.001 JIB-04+IR versus IR (2-way ANOVA for tu-
mor growth in the left panel, and Kaplan-Meier for
survival in the right panel).
(C and D) Tumor tissues were harvested at time of
death (n = 4 for vehicle and JIB-04) or 12 hr after the
last dose of treatment (n = 3 for IR and JIB-04+IR),
tumor extracts were prepared, and H3K4me3 de-
methylase activity was measured. *p < 0.05 for IR
versus no IR (C); *p < 0.05 for vehicle+IR/vehicle
versus JIB-04+IR/JIB-04 alone (D) (t test).
See also Figure S8 and Table S3.robust increase in survival was also seen in A549 xenograft tu-
mors (Figure 7B), fully confirming these results in a second
model. Furthermore, lysates of tumors harvested from each
treatment group at the time of sacrifice showed a significant in-
crease in H3K4me3 demethylase activity after IR and an inhibi-
tion of this increase by JIB-04 (Figures 7C and 7D), consistent
with our earlier observations in cells (Figure 5C), suggesting
that the KDM5B pathway is also relevant in vivo. No overt toxic-
ities were observed in the combination treatments (Figure S8).
Finally, we queried lung cancer The Cancer Genome Atlas
(TCGA) data to determine whether levels of KDM5B correlate
with the clinical response to radiation therapy in human patients.
We found that high levels of KDM5B correlate with radioresist-
ance among patients with lung squamous cell carcinomas, while
no significant correlationwas seenwith the other members of the
KDM5 or KDM4 subfamilies (Table S3).
DISCUSSION
Jumonji enzymes have been reported to play roles in DNA
repair pathways. It has been suggested, for example, that chro-
matin dissociation of the H3K36me2 demethylase KDM2A in
response to ATM phosphorylation is critical for the NHEJ pro-
cess (Cao et al., 2016; Fnu et al., 2011). Likewise, KDM4Adegradation is required at sites of DNA damage, since it com-
petes with 53BP1 for binding to H4K20me through its Tudor
domain (Mallette et al., 2012). In this study, we have uncovered
a role for KDM5B in demethylation of H3K4me3 at and
near sites of DNA damage and an IR-induced increase in
H3K4me3 demethylase activity in lung cancer cells and in tu-
mors in vivo. We show that the catalytic activity of KDM5B is
required to mediate full and efficient repair of DSBs. Impor-
tantly, we have identified a pharmacological preclinical strategy
to impair this activity in vivo leading to radiosensitization of
tumors by the Jumonji inhibitor JIB-04. Mechanistically, inhibi-
tion of KDM5B activity results in defective recruitment of repair
factors, lower efficacy of repair by both HR and NHEJ, and
consequently radiosensitization of lung cancer cells and
tumors. Knockdown of KDM5B, in turn, phenocopies the
effects of pharmacological inhibition of this enzyme on DNA
repair, consistent with the radiosensitizing effects of silencing
KDM5B in oral carcinomas (Lin et al., 2015). Overexpression
of KDM5B reverts both the DNA repair defects and the radio-
sensitization induced by JIB-04 treatment, indicating KDM5B
is the main target of JIB-04 inhibition under conditions of IR
damage in DNA-repair-proficient cells. Other actions of JIB-04
in addition to KDM5B inhibition may possibly further enhance
the radiosensitization phenotype.Cell Reports 25, 1040–1050, October 23, 2018 1047
Our overall findings are in agreement with the reported impor-
tance of KDM5B in maintaining genome stability (Li et al., 2014)
and support the idea that H3K4me3 demethylation and partial
chromatin condensation may be required for efficient recruit-
ment of repair factors at active chromatin (Burgess et al., 2014;
Li et al., 2014; Seiler et al., 2011). The enhanced response to ra-
diation triggered by inhibition of KDM5B activity appears to be
the result of inefficient DNA repair. Upon Jumonji inhibition,
repair factor recruitment and resolution of DSB are defective
due to the accumulation of H3K4me3 marks at transcriptionally
active regions harboring damage. Specifically, we observe de-
layed phospho-DNA-PKcs and RAD51 recruitment and defects
in resolution under conditions that accumulate H3K4me3 near
DSB, in conceptual agreement with the reported defect in
Ku70 and BRCA1 binding at DBS after KDM5B knockout in os-
teosarcoma cells (Li et al., 2014). In NSCLCs, however, we do
not observe measurable changes in Ku70 at sites of DSBs
induced by IR. Based on this, we propose that the DNA damage
response superactivates KDM5B to demethylate H3K4me3 at
transcriptionally active genomic regions harboring DNA DSBs.
This action of KDM5B would halter transcription at these open
chromatin sites until repair is finalized, consistent with the sug-
gestion that there is active demethylation of H3K4me3 at sites
of DSB (Seiler et al., 2011). This model complements the existing
view that ATM activation leads to the phosphorylation of the ENL
transcriptional elongation factor, the recruitment of the PRC1
complex, and the ubiquitination of H2A at transcriptionally active
sites harboring DNA damage to silence transcription (Ui et al.,
2015). Our data suggest that in addition, the active demethyla-
tion of H3K4me3 at these sites by KDM5B is a likely necessary
parallel step that allows the haltering of transcription and efficient
repair factor binding at and near DSB (Li et al., 2014).
The engagement of KDM5B in the cellular response to DSBs
induced by IR defines a therapeutic opportunity. As we show
here, pharmacological inhibition of its demethylase activity with
JIB-04 or PBIT results in tumor cell radiosensitization. The in vivo
synergy we observe between IR and JIB-04 treatment, together
with the robust extension of lifespan and increased survival even
weeks post treatment, points to a clear clinical potential for this
type of approach. Our finding that lung cancer patients whose
squamous cell tumors express high levels of KDM5B are
more refractory to radiation therapy highlights the clinical
relevance of our observations. Our study suggests this radiore-
sistance may be overcome by pharmacological inhibition of
KDM5 enzyme activity, establishing a paradigm where histone
methylation at DSBs can be safely targeted to modulate the
response to IR.STAR+METHODS
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expression. Oncogene 33, 734–744.
STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Anti–phospho-Histone gH2AX (Ser139) Millipore Cat#05-636; RRID: AB_309864
Anti–tri-methyl-histone H3K9 Millipore Cat#07-442; RRID: AB_310620
Anti-tri-methyl-histone H3K4 Millipore Cat#07-473; RRID: AB_1977252
Anti-53BP1 Cell Signaling Technology Cat#4937; RRID: AB_106954558
Anti-KDM5B Cell Signaling Technology Cat#3273; RRID: AB_1264191
Anti-KDM4B Cell Signaling Technology Cat#D7E6; RRID: AB_11140642
Anti-mouse IgG-HRP linked Cell Signaling Technology Cat#7076; RRID: AB_330924
Anti–Rad51 Abcam Cat#ab-213; RRID: AB_302856
Anti-DNA-PKcs p-T2609 Abcam Cat#ab-18356; RRID: AB_444447
Anti-H3 Abcam Cat#ab-12079; RRID: AB_298834
Anti-HA (3F10) Roche Cat#11867423001; RRID: AB_10094468
Anti-Flag (M2) Sigma-Aldrich Cat#F1804; RRID: AB_262044
Anti-tubulin Sigma-Aldrich Cat#T5168; RRID: AB_477579
Anti-KDM5A Bethyl Cat#A300-897A: RRID: AB_2234038
Anti-KDM4A Bethyl Cat#A300-861A; RRID: AB_069461
Anti-KDM5C Novus Biological Cat#NB100-55328; RRID n/a
Anti-Ku70 Santa Cruz Cat#sc-1487; RRID: AB_632614
Anti-goat IgG HRP conjugated Santa Cruz Cat#sc-2020; RRID: AB_631728
Anti-GAPDH GeneTex Cat#GTX100118; RRID: AB_1080976
Alexa Fluor 488–conjugated goat anti-Rabbit Thermo Fisher Cat#A-11034; RRID: AB_2576217
Alexa Fluor 555–conjugated goat anti-mouse Thermo Fisher Cat#A32727; RRID: AB_2633276
Rhodamine red–conjugated goat anti-mouse Thermo Fisher Cat#R-6393; RRID: AB_2556550
IRDye 680RD –conjugated goat anti-mouse LI-COR Biosciences Cat#925-68070; RRID: AB_2651128
IRDye 800 CW –conjugated goat anti-rabbit LI-COR Biosciences Cat#925-32211; RRID: AB_2651127
Chemicals, Peptides, and Recombinant Proteins
JIB-04 Synthesized in-house
(Wang et al., 2013)
N/A
GSK-J4 Tocris Bioscience Cat#4594
GSK-J5 Tocris Bioscience Cat#4689
PBIT Sigma-Aldrich Cat#PH009215
I-SceI enzyme New England Bio Labs Cat#R0694L
Critical Commercial Assays
Ingenio Electroporation kit Mirus Bio LLC Cat#MIR 50115
H3K4me3 demethylation kit Epigentek Cat#P-3083
H3K9me3 demethylation kit Epigentek Cat#P-3081
EZ Magna ChIP A/G Chromatin Immunoprecipitation Kit Millipore Cat#17-100086
Experimental Models: Cell Lines
U-2 OS Dr. Sandeep Burma N/A
LNCaP Dr. Phil Thorpe N/A
H1299 Dr. John D. Minna N/A
A549 Dr. John D. Minna N/A
HCC95 Dr. John D. Minna N/A
HCC1195 Dr. John D. Minna N/A
(Continued on next page)
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REAGENT or RESOURCE SOURCE IDENTIFIER
HCC2279 Dr. John D. Minna N/A
HCC1719 Dr. John D. Minna N/A
HBEC30KT Dr. John D. Minna N/A
HBEC3KT Dr. John D. Minna N/A
Experimental Models: Organisms/Strains
Female athymic nude mice (nu/nu, 5–6 weeks old) The Jackson Laboratory Stock #: 002019
Oligonucleotides
siRNA for Knock Down experiments See Table S5 N/A
Oligonucleotides for RealTime Quantitative PCR See Table S6 N/A
Recombinant DNA
NHEJ-I reporter construct Seluanov et al. (2010) N/A
HR reporter construct Seluanov et al. (2010) N/A
Flag-KDM5B construct Dr. Ralf Janknecht N/A
HA-KDM5A construct Addgene plasmid #14799
HA-KDM4B construct Addgene plasmid #24181
HA-KDM4A construct Dr. Yang Shi N/A
Software and Algorithms
ImageJ NIH https://imagej.nih.gov/ij/download.html
CellProfiler Broad Institute http://cellprofiler.org/releases/CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Elisabeth
D. Martinez (elisabeth.martinez@utsouthwestern.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Lines
Human NSCLCs cell lines and immortalized non-cancerous human bronchial epithelial cells were kindly provided by Dr. John D.
Minna. H1299 (male), A549 (male), HCC1719 (male), HCC95 (male), HCC1195 (male), HCC2270 (female) cancer cell lines were main-
tained in RPMI media with 5% fetal bovine serum. HBEC30KT (female) and HBEC3KT (female) human bronchial epithelial cells were
cultured in KSFM media with EGF and pituitary extract (KSFM supplements from GIBCO) in a humidified 37C incubator with 5%
CO2. U-2 OS (female) cells were kindly provided by Dr. S. Burma and maintained in DMEM media with 10% of FBS. LNCaP
(male) cells, a gift of the late Phil Thorpe, were cultured in RPMI media supplemented with 10% FBS and penicillin-streptomycin.
All cell lines were verified by DNA fingerprinting with the Promega Fusion system (Cat# DC2408) which consists of 24 short tandem
repeat (STR)markers. These loci collectively provide a genetic profile with a randommatch probability of 63 1029. Fingerprints were
compared against our database ofmore than 2000 reference fingerprints whichwere collected fromATCC, DSMZ, JCRB, and RIKEN
(Capes-Davis et al., 2013) and from our own resources (Gazdar et al., 2010). A match is called between two fingerprints when at least
80% of the alleles are identical according to the shared allele match algorithm defined by ICLAC. Mycoplasma contamination was
tested periodically using e-Myco Mycoplasma PCR dectection kit (iNtRON Biotechnology, 25235).
Mice
Athymic nude mice female mice between 5 to 6 weeks were maintained with normal diet under standard animal housing condition.
Animal experiments were carried out under approved IACUC protocols and followed UTSW animal care procedures (protocol num-
ber: APN2017-102260). NSCLC cells were injected subcutaneously (53 106 cells in 100 mL PBS H1299, 23 106 in 100 mL PBS A549
cells) into the right posterior leg of mice. Treatment was initiated when the subcutaneous tumors reached an average size of 150 to
200 mm3. Mice were treated with JIB-04 (50 mg/kg/day) by oral gavage or with vehicle (12.5% Cremophor EL, 12.5% DMSO as an
aqueous suspension); radiation was administered 4 hours after treatment. The treatment regimen consisted of a total of 12 doses of
drug and/or IR given every other day. Tumor growth delay and the dose enhancement factor (DEF) were then determined. Body
weight and general health were monitored every other day. Standard survival criteria was applied including severe lethargy, 20%
weight loss, tumor burden > 2,000 mm3 and/or difficulty breathing. Survival data was analyzed using GraphPad Prism software.e2 Cell Reports 25, 1040–1050.e1–e5, October 23, 2018
All differences between treatment groups were analyzed by two-way ANOVA. For demethylase assays, animals were sacrificed 16 h
after the last dose of treatment and tumors harvested and frozen.
METHOD DETAILS
Colony formation assays
Clonogenic cell survival of cells treated with IR alone or in combination with Jumonji inhibitors JIB-04, GSKJ-4, or PBIT, was analyzed
by standard colony formation assays. JIB-04 Z-isomer, GSK-J5 and DMSO were used as controls. Cells were serially diluted to
appropriate concentrations as shown in Table S4 and plated into 60-mm dishes in triplicate and allowed to attach for 4 h. Then cells
were treated with the indicated drugs and irradiated 4 h later with graded doses of radiation for concurrent treatment (all experiments
except Figure S1C), or irradiated first and 4 h later drugs added for post-treatment for comparison (Figure S1C). All cells were irra-
diated at room temperature in ambient air using a 137 Cs source (Mark 1-68 irradiator, JL Shepherd & Associated). Surviving colonies
were stained with crystal violet 10 to 14 days later and colonies larger than approximately 50 cells were counted. The surviving
clonogenic fraction of irradiated cells was normalized to the plating efficiency of un-irradiated controls. The data are presented
as the mean ± SD. The curve S = e  (aD + bD2) was fitted to the experimental data using a least square fit algorithm with Sigma
Plot 11.0 (Systat Software, Inc.). Inhibitor alone treatments were used to set the surviving fraction at 1.
Immunofluorescence staining
NSCLCs were seeded onto Lab-Tek II Chamber Slides (Thermo Fisher) and 24 hours later pretreated with JIB-04 or DMSO for 4 h.
Then cells were exposed to a total dose of 2 Gy (gH2AX and 53BP1) or 10 Gy (RAD51 and DNAPKcs p-T2609) radiation. Cells were
fixed in 4% formaldehyde/PBS for 15 min, permeabilized with 0.5% Triton X-100 for 15 min on ice, and blocked with 5% bovine
serum albumin in PBS for 1 h. The slides were incubated with an antibody against phospho-Histone gH2AX (1:1000, 3 h at room
temperature), 53BP1 (1:500, 3 h at room temperature), Rad-51 (1:500, 48 h 4C) or DNAPKcs p-T2609 (1:500, 48 h 4C). Alexa Fluor
488–conjugated goat anti-Rabbit, Alexa Fluor 555–conjugated goat anti-mouse or rhodamine red–conjugated goat anti-mouse sec-
ondary antibodies were used (1:1000, 1h at room temperature). Slides were mounted in a Vectashield mounting medium containing
40,6-diamidino-2-phenylindole (DAPI). Cells were imaged on a Zeiss upright fluorescent microscope. Foci counting was performed
on the resulting images using the CellProfiler (CellProfiler.org) open-source cell image analysis software (algorithm available upon
request) in a blinded fashion. Quantification was validated in several cases manually with ImageJ in a blinded fashion by two
independent investigators.
Knockdown and overexpression studies
33 106 cells were transfected by electroporation using the Amaxa Nucleofector (program X-005) and the Ingenio Electroporation kit.
For knock down experiments, cells were transfected with siRNA duplexes targeting the corresponding Jumonji enzyme or scrambled
siRNA mixes with 250 nM final concentration. Knock down siRNA were from Sigma-Aldrich or QIAGEN and are summarized in
Table S5. Knock-down cells were cultured for 48h before quantification of expression or further assays. For overexpression exper-
iments, cells were transfected with pCMVHA-KDM4A, pCMVHA-KDM4B, pCMVHA-KDM5A, pCMVHA-KDM5B, or pcDNA3 plas-
mids (3mg), then allowed to recover in culture for 24h before proceeding with measurements of expression or further assays.
Western blot analysis
H1299 cells were transfected with siRNA or expression plasmids as above, harvested in RIPA buffer containing PhosSTOP 1X
(Roche) and proteinase inhibitor cOmplete ULTRA Tablets, (Roche), the debris was pelleted (20,000 RCF x 15min), protein quantified
and equal amounts of protein run on SDS acrylamide gels. Protein was transferred to nitrocellulose or PVDFmembranes and blotted
using the indicated antibodies. Gels were imaged using using Odyssey infrared imaging or Li-Cor Odyssey Fc systems.
Quantitative RT-PCR
RNA of H1299 cells transfected with siRNA or expressing plasmids was extracted with RNeasy technology (QIAGEN). RNA was
quantified, DNase treated and reverse transcribed. The cDNA was then amplified with Sybr green chemistry in real time quantitative
PCR assays (Applied Biosystems) using validated primers specific for the human genes of interest. Reactions were performed on an
ABI Prism 7900HT, with an initial 2 min pre-incubation at 50C, followed by 10 min at 95C and then 40 cycles of 95C for 15 s and
60C for 1 min. 18S ribosomal RNA and cyclophilin were used as reference genes as before (Wang et al., 2013). Data were analyzed
using theDDCtmethod (Bookout et al., 2006). Gene expression levels were then expressed as fold-induction over untransfected con-
trol cells. Reactions were run in triplicate and error bars represent experimental error, unless otherwise specified. Several distinct
biological replicates were analyzed with equivalent results. Primer sequences are given in Table S6.
NHEJ and HR assays
The green fluorescent protein repair assay was performed as described by Seluanov et al. (2010). To generate reporter cell lines,
2 million H1299 cells were transfected with 0.5 mg of linearized NHEJ-I, or HR reporter constructs using the Amaxa Nucleofector pro-
gram X-005. G418, at 1mg/ml, was added to the media 1 day post-transfection and stably transfected populations used two weeksCell Reports 25, 1040–1050.e1–e5, October 23, 2018 e3
post selection. Then transient expression of the I-SceI endonuclease was used to generate a DNA DSB at the integrated GFP gene
sequences. Briefly, H1299 cells containing the NHEJ or the HR constructs treated for 4 h with JIB-04 or DMSOwere transfected with
the pCMV3xnls-I-SceI (5 mg, functional endonuclease) and a pN1-mCherry plasmid (0.05 mg) as transfection control as previously
stated. To measure NHEJ and HR, cells were harvested, resuspended in 1 mL 1xPBS, put on ice, and analyzed on a BD FACScan
instrument for GFP and mCherry expression. GFP and mCherry fluorescence was quantified using FlowJo software. DNA repair
efficiency was calculated from the number of GFP-positive cells divided by the number of mCherry-positive cells. For the extrachro-
mosomal assay in U-2 OS cells, NHEJ-I and HR plasmids were in vitro linearized by digestion with the I-SceI enzyme (NEB).
Then, 1 million U-2 OS cells were transfected with 0.25 mg and 0.5 mg respectively of the linearized plasmids and the pN1-mCherry
plasmid (0.025 mg) using the Amaxa Nucleofector program X-001. Cells were seeded in the presence of 800 nM JIB-04. Finally, 12 h
and 24 h after seeding, DNA repair was analyzed as described above for H1299 stably transfected cells.
Cell cycle analysis
250,000 NSCLCs were seeded in 6 wells plates, 24 h latter cells were pretreated with JIB-04 as indicated or DMSO for 4 h and
exposed to a total dose of 2 Gy. Then cells were collected 15min, 6 h or 12 h post IR and fixed using 75% ethanol at 20C for a
minimum of 24 hours. The fixed cells were resuspended in PBS and incubated with 20 mL 1 mg/ml RNase A (Sigma) and
25 mgml/ml propidium iodide (Sigma) for 30min at room temperature. Experiments were done in triplicate. 20,000 cells were counted
and the proportion of cells in different cell cycle phases was analyzed using the software Flowjo.
Histone demethylase activity assay
For histone demethylase activity determination in cells, 2x106 H1299 cells were seeded in P150 plates. After 24 h, cells were pre-
treated with indicated dose of JIB-04 or DMSO for 4h, irradiated with 8 Gy of radiation in a single dose. Note that the cell number/
density and amount of IR used was higher for demethylase assays than for radiation response curves which are based on low density
colony formation assays or for foci resolution slides. Enzyme activity was not detectable at the lower cell numbers and thus both cell
number and IR dose were increased to obtain similar levels of DNA damage per cell area. Cells were harvested 15 min after IR and
pellets resuspended in cold PBS containing PhosSTOP 1X (Roche), cOmplete ULTRA Tablets, EDTA-free, 1X (Roche) and 1 mM
Wortmannin (Sigma-Aldrich). Cell suspensions were sonicated (3X 4 s, Ultrasonic Processor XL Sonicator), debris pelleted
(15 min at 20,000 rcf.). For tumor extract preparation, tissues were collected 16 h after last dose of radiation and frozen. Twenty
to 50 mg of frozen tumor tissue was dissociated in cold PBS supplemented as above with 2X EDTA-free protease inhibitors and
10 mM Wortmannin then then homologized by ultra-sonication using a TissueLyserII (QIAGEN, 2x 1min at 0.03/sec frequency).
Supernatants after centrifugation (18,000 g for 10 min) were snap-freezed in liquid nitrogen until analysis. Protein in lysates were
quantified, and equal amounts of protein (2.5 mg for cell extracts or 8.0 mg for tumor extracts) were incubated with a histone
H3K4me3 or H3K9me3 substrate in a reaction buffer containing 50 mM HEPES pH 7.5, 0.01% Tween 20, 5 mM (NH4)2Fe(SO4)2
for cell extracts only, 1 mM a-ketoglutarate and 2 mM sodium L-ascorbate for 1 h at 37C. Specific immune-detection of
the H3K4me2 or H3K9me2 product was measured using the Epigentek kit P-3083 for H3K4me3 demethylation or P-3081 for
H3K9me3 demethylation. Background readings were given by heat inactivated extracts.
Immunoprecipitation
For gH2AX immunoprecipitation 13 107 H1299 cells were seeded in P150 plates. Next day cells were preincubated with 300 nM JIB-
04 for 4 h and then irradiated with 20 Gy. Due to the higher density of cells needed to obtain sufficient material to immunoprecipitate,
we increased both JIB-04 dose and IR dose to obtain similar level of damage and KDM inhibition in the dense culture. Media was
removed from cells, cells washed with PBS and fixed with 3% w/v PFA, 2% w/v sucrose in PBS for 1 min. Then cells were washed,
scraped into media, pelleted by centrifugation (at 500xg for 2 min) and washed with cold PBS containing PhosSTOP 1X (Roche),
cOmplete ULTRA Tablets, EDTA-free, 1X (Roche) and 1 mM Wortmannin (WM, Sigma-Aldrich). Cell pellets were re-suspended in
2.5 3 the packed cell volume of Nucleosome Preparation Buffer (NPB, 10mM HEPES [pH 7.9], 10 mMKCl, 1.0 mM CaCl2,
1.5 mM MgCl2, 0.34 M sucrose, 10% glycerol, 1mMDTT, 0.1% Triton X-100) containing PhosSTOP 1X (Roche), cOmplete ULTRA
Tablets, EDTA-free, 1X (Roche), 1 mMWortmannin (WM, Sigma-Aldrich) and 100 U ml1 micrococcal nuclease (MNase), and incu-
bated at 37C for 45min (note:WM is required to block in vitroDNA-PK/ATM activation byMNase-produced DSBs). An equal volume
of Nucleosome Solubilization Buffer (NSB = NPB + 2% [v/v] NP-40, 2% [v/v] Triton X-100, 600 mMNaCl) was then added. Samples
were vortexed, sonicated briefly and centrifuged at 10,000 rpm for 10 min. Protein levels were quantified, and 2 mg of the resulting
supernatants were incubated with 2 ml of anti-gH2AX monoclonal antibody overnight at 4C with rotation. Immunocomplexes were
pulled down by adding 45 ml of protein G-Sepharose for 3 h at 4C, washed three times with wash buffer (1X NPB + 1 X NSB),
resuspended in 2x SDS sample buffer and incubated at 75C for 2 h to reverse cross-links. Equal amounts of protein run on
4%–12% SDS acrylamide gels. Protein was transferred to nitrocellulose membranes and blotted for phospho-Histone gH2AX
(Ser139), Ku-70, H3K4me3 and H3K9me3. IRDye 680RD and IRDye 800 CW (LI-COR Biosciences) or and HRP-conjugated second-
ary antibodies were used and images captured with the Odyssey infrared imaging system. Quantification was done using ImageJ or
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Chromatin immunoprecipitation/Re-precipitation
H1299 harboring the NHEJ construct were plated at 107 cells/P150 for 17-18 h then treated with DMSO or JIB-04 (300 nM) for 4 h.
Cells were trypsinized and transfected with pCMV3xnls-I-SceI (5 mg plasmid/3x106 cells/electroporation reaction as stated above).
After electroporation, cells were plated at 107 cells/P150 with continued treatment to allow for I-SceI expression. 19-20 h later cells
were collected, fixed, washed and resuspended in NBP as stated for immunoprecipitation of gH2AX. Chromatin was generated by
adding 17 units of MNase/ mL and incubated at 37C for 30 min. The reactions were stopped by EDTA (70 mM final concentration).
Nuclei were collected by spinning at 16,000 g for 10 minutes at 4C. Buffers used for ChIP, reChIP and protein A/G beads came from
the EZMagna ChIP kit (Millipore 17-100086) unless stated. Nuclei pellets were dissolved in 2.53 the packed cell volume in SDSChIP
lysis buffer supplemented with phosphatase and proteinase inhibitors and Wortmanin as above. Chromatin solutions were rolled at
4C for 10min, the insolublematerials were removed by spinning at 21,000 g for 10min. 800 mg of protein was used per ChIP reaction.
For ChIP, 15 uL of 1 mg/mL of gH2AX antibody was used per reaction except in parallel no antibody controls. Lysates were incubated
with agitation at 4C overnight. Protein A/G beads were added and incubated with agitation for 2-3 hours at 4C. Beads were
collected andwashed according to themanufacture’s instruction. ChIP products were eluted from the beads using 300 mL of ReChIP
elution buffer (2%SDS, 15mMDTT in TE) with agitation at 37C for 1 h. 150 mLwas diluted 21 times in reChIP dilution buffer (30ug/mL
BSA in ChIP dilution buffer) supplemented as before. The re-ChIP solutions were precleared with protein A/G then split into two parts.
8 mL of H3K4me3 antibody or no antibody were added. Both tubes were incubated overnight with agitation at 4C and processed as
in the ChIP steps. re-ChIP products were eluted from the beads using 250 mL of ChIP elution buffer (1% SDS in 100 mM NaHCO3)
twice at room temperature with agitation. re-ChIP inputs and re-ChIP eluates were brought up to 500 mL with ChIP elution buffer and
uncross-linked at 65C overnight with 200 mM NaCl. Samples were treated with DNase free RNase (1 mL of 10 mg/mL for 30 min at
37C) followed by proteinase K (1 mL of 20 mg/mL at 45C for 1 h) in the presence of 10 mM of EDTA and 40 mM Tris, pH6.5. DNA
was purified using Phenol:Chloroform:Isoamyl alcohol extraction and quantified by qPCR using validated primers (see Table S6). The
control genomic primer has been previously characterized (Aymard et al., 2014).
TCGA Analysis
Clinical information and gene expression (RNA-Seq) data were obtained from The Cancer Genome Atlas (TCGA) for lung squamous
cell carcinoma (LUSC). The gene expression of Jumonji genes from radiated patients with complete response (defined as radiosen-
sitive) were compared with radiated patients with radiographic progressive disease or partial response (defined as radioresistant)
using t tests controlling for the equality of variances as described (Pen˜a-Llopis et al., 2011).
QUANTIFICATION AND STATISTICAL ANALYSES
All numerical results are reported asmean ± standard error of themean (SEM) or asmean + standard deviation (SD). Unless otherwise
specified, unpaired 2-sided Student’s t test, one-way analysis of variance followed by post-tests, Kruskal-Wallis or Dunn’s
(GraphPad Prism Software), were used for statistical analyses, as indicated. Clonogenic survival curves weremodeled with the linear
quadratic equation (S = e[aD + bD2]) for radiation treatment and a four-parameter variable slope regression for drug toxicity.
Differences with p values lower than 0.05 were considered as statistically significant. The exact statistical analyses used, the
significance value, the sample size (n) and number of biological replicates are indicated in each figure or figure legend.Cell Reports 25, 1040–1050.e1–e5, October 23, 2018 e5
